Disodium Cantharidinate and Vitamin B6 Injection Adjunct with Platinum-Based Chemotherapy for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis

Table 1

Summary of trial characteristics included in the meta-analysis.

Study	N(T/C)	Age		Physical	Clinical stage		Interventions		Methods score	Outcomes
		T	C		T	C	T	C
Wen et al., 2012[15]	34/34	32-70(58)		KPS≥60	III(25),IV(43)		DCVB6 50 ml/day, for 10 days + control	DP	8	①③④⑥
Song et al., 2012[16]	29/29	35-81(52.6)	28-85(53.4)	KPS>60	IIIb(20),IV(9)	IIIb(18),V(11)	DCVB6 30 ml/day, for 14 days + control	TP	7	①②
Zhang, 2012[17]	35/30	53-78(64)	51-76(62.5)	KPS≥60	IIIb(22),IV(13)	IIIb(19),IV(11)	DCVB6 30 ml/day, for 14 days + control	TP	9	①②④⑤⑥
Cao et al., 2013[12]	40/39	45-73(67)	47-75(65)	KPS≥60	IIIb(18),IV(22)	IIIb(20),IV(19)	DCVB6 40 ml/day, for 14 days + control	GP	8	①
Dong et al., 2013[13]	60/60	41-70(57.13)	40-72(56.27)	KPS≥60	III(22),IV(38)	IIIb(26),IV(34)	DCVB6 50 ml/day, for 10 days + control	DP	7	①②③④⑥
Wang et al., 2013[14]	42/38	32-70(42)	31-58(44)	KPS≥60	III(24),IV(18)	III(22),IV(16)	DCVB6 50 ml/day, for 14 days + control	NP	8	①④⑥
Sun et al., 2013[18]	36/32	49-68(51)	52-67(53)	KPS≥60	NR		DCVB6 50 ml/day, for 10 days + control	DP	8	①②④⑤⑥
Yuan et al., 2013[19]	27/26	61	60	KPS>70	NR		DCVB6 40 ml/day, for 14 days + control	DP, TP, GP or NP	9	①②
Zeng et al., 2014[20]	21/21	38-76(56)	40-74(58)	KPS>60	III(9),IVa(12)	III(8),IVa(13)	DCVB6 50 ml/day, for 14 days + control	DP	9	②④⑤⑥
Jia et al., 2014[21]	19/16	45-63		NR	NR		DCVB6 20 ml/day, for 15 days + control	DP	7	①④⑤
Dong et al., 2014[22]	48/46	26-75(56.5)	38-74(57.3)	KPS>30	III(21),IV(27)	III(19),IV(27)	DCVB6 50 ml/day, for 10 days + control	GP	8	①②③④⑤⑥
Chen et al., 2015[23]	42/42	45-78	43-76	KPS≥60	IIIb(30),IV(12)	IIIb(30),IV(12)	DCVB6 40 ml/day, for 10 days + control	GP	8	①②④⑤⑥
Wang et al., 2015[24]	76/78	71.3	72.4	KPS≥60	III(80),IV(74)		DCVB6 40 ml/day, for 14 days + control	AP	9	①②④⑥
Liu et al., 2015[25]	49/49	28-74(52.1)	30-75(52.6)	NR	III(27),IV(22)	III(25),IV(24)	DCVB6 25 ml/day, for 14 days + control	GP	8	①②③④⑤⑥
Li, 2015[26]	36/36	40-80(56.9)		NR	IIIb(42),IV(30)		DCVB6 50 ml/day, for 15 days + control	TP	9	①
Hu et al., 2016[27]	28/28	38-72(55)	39-73(56)	KPS≥70	NR		DCVB6 40 ml/day, for 10 days + control	GP	8	①②④⑤⑥
Li et al., 2016[28]	40/40	20-74(54.35)	28-76(54.39)	KPS≥70	IIIb(27),IV(13)	IIIb(25),IV(15)	DCVB6 30 ml/day, for 14 days + control	GP	8	①②④⑤⑥
Du et al., 2017[29]	30/30	52-78(65.27)	51-76(65.29)	NR	NR		DCVB6 50 ml/day, for 10 days + control	GP	8	①
Chen, 2017[30]	31/31	40-71(55.27)	41-70(54.52)	KPS≥60	III(12),IV(19)	III(13),IV(18)	DCVB6 50 ml/day, for 10 days + control	NP	8	①③④⑥

DP: docetaxel + cisplatin, TP: paclitaxel + cisplatin, GP: gemcitabine + cisplatin, NP: navelbine + cisplatin, AP: pemetrexed + cisplatin, ① ORR, ② KPS, ③ clinical symptom, ④ WBC toxicity, ⑤ platelet toxicity, and ⑥ vomiting.